Sun Pharma to Acquire Organon in $11.75 Billion Deal to Boost Global Women’s Health Portfolio 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition 
U.S. Budget Airlines Seek $2.5 Billion Government Aid Amid Rising Jet Fuel Costs 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
U.S. Warns Allies Over Alleged Chinese AI IP Theft Linked to DeepSeek 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
Strait of Hormuz Shipping Crisis Deepens as Traffic Plunges Amid Iran-U.S. Tensions 
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
LUND, Sweden, Feb. 18, 2016 --
Laquinimod
- In April, it was announced that the first patient was enrolled to ARPEGGIO, which is evaluating laquinimod's potential for treatment of primary progressive multiple sclerosis (PPMS)
- In June, it was announced that the company was to focus its operations on the laquinimod projects and adjust the organization accordingly
- In June, it was announced that the Phase 3 laquinimod study CONCERTO was fully enrolled
- In October, Teva presented data concerning laquinimod for the treatment of multiple sclerosis at the ECTRIMS congress
- The high dose group in the clinical studies CONCERTO, ARPEGGIO and LEGATO has been discontinued due to cardiovascular events
- The study results from both the pivotal clinical Phase 3 study CONCERTO in relapsing remitting multiple sclerosis (RRMS) and the Phase 2 study ARPEGGIO, evaluating laquinimod for the treatment of primary progressive multiple sclerosis (PPMS), are expected in the first half of 2017
Tasquinimod
- In April, it was announced that Active Biotech and Ipsen were to discontinue development of tasquinimod for the treatment of prostate cancer
- The final results from the 10TASQ10 study were presented in September 2015 at the ECC conference and demonstrated that while the primary endpoint was reached and tasquinimod treatment resulted in a prolonged radiographic progression-free survival (rPFS), 7.0 vs. 4.4 months, the positive effect on rPFS did not translate into an improved OS
ANYARA, Paquinimod (57-57) and ISI
- Out-licensing activities are continuing
Financial summary
| MSEK | Oct - Dec | Jan. - Dec. | ||||
| 2015 | 2014 | 2015 | 2014 | |||
| Net sales | 5.0 | 2.9 | 16.3 | 10.4 | ||
| Operating loss | -28.2 | -55.6 | -177.9 | -228.5 | ||
| Loss for the period | -40.8 | -57.0 | -193.5 | -231.5 | ||
| Loss per share, before and after dilution (SEK) | -0.45 | -0.73 | -2.15 | -3.02 | ||
| Cash and cash equivalents | 103.6 | 328.5 | ||||
For further information, please contact:
Tomas Leanderson, President and CEO
Tel: +46 (0)46 19 20 95
Hans Kolam, CFO
Tel: +46 (0)46 19 20 44
Active Biotech AB
(Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund, Sweden
Tel: +46 (0)46 19 20 00
Fax: +46 (0)46 19 11 00
The report is also available at www.activebiotech.com.
Active Biotech AB Year-end report January - December 2015 http://hugin.info/1002/R/1986986/729147.pdf
HUG#1986986
